International Journal of Environmental and Biological Sciences Articles Publishing terms and rules Vol. 1 No. 4 (2026): Fourth Issue - October 2026 2026-10-31

Advances and Prospects in Next-Generation CRISPR-Based Cancer Diagnostics CRISPR

01Abstract

The development of CRISPR-based diagnostic technologies has created new opportunities for the sensitive and programmable detection of cancer-associated nucleic acids. By coupling guide-RNA-directed target recognition with collateral cleavage by Cas12 or Cas13 effectors, these platforms convert specific molecular interactions into fluorescent, colorimetric, electrochemical, or lateral-flow signals. When combined with target pre-amplification strategies, CRISPR assays may detect low-abundance mutations and RNA biomarkers in liquid-biopsy specimens. This review provides a concise overview of the molecular principles of CRISPR diagnostics, target recognition mechanisms, amplification strategies and emergent assay formats, with a particular emphasis on Cas12- and Cas13-based systems. Includes the applications of circulating tumor DNA, microRNAs, extracellular vesicles, early detection, tumor profiling, and treatment monitoring. Besides the analytical, pre-analytical, regulatory and implementation barriers currently limiting clinical translation, integrated microfluidic and point-of-care platforms are also discussed. The analytical performance described is promising, but many of the cancer-related assays are still at the proof-of-concept stage and require validation in larger prospective, multicenter cohorts. Before CRISPR-based tests can be used as routine diagnostics, standardized sample processing, reference materials, reproducible assay design and comparisons with established clinical methods will be imperative.


Keywords: cancer diagnostics; circulating tumor DNA; CRISPR-Cas; microRNA; liquid biopsy; Cas12a; Cas13; extracellular vesicles

Keywords cancer diagnostics circulating tumor DNA CRISPR-Cas microRNA liquid biopsy Cas12a Cas13 extracellular vesicles

02Authors

Sahar Mohammed Jawad
Middle Euphrates Cancer Research Unit, College of Medicine, University of Kufa, Iraq
Emad Kareem Alsabari
Middle Euphrates Cancer Research Unit, College of Medicine, University of Kufa, Iraq
Alaa Mohammed Khaleel3
Middle Euphrates Cancer Research Unit, College of Medicine, University of Kufa, Iraq
Dhefaf Hameed Al-Mudhafar
Middle Euphrates Cancer Research Unit, College of Medicine, University of Kufa, Iraq
Hasanain Ali Shubbar
Jabir Ibn Hayyan University for Medical and Pharmaceutical Sciences, Faculty of Medical Science, Academic Center for Epidemiological Diseases , Najaf, Iraq
Sara salih hassan
Jabir Ibn Hayyan University for Medical and Pharmaceutical Sciences, Faculty of Medical Science, Academic Center for Epidemiological Diseases , Najaf, Iraq
Dr. Samer A. MH. Al-Hilali
Middle Euphrates Cancer Research Unit, College of Medicine, University of Kufa, Iraq
Eman Hassani Shabat
Middle Euphrates Cancer Research Unit, College of Medicine, University of Kufa, Iraq
Tabarek Hadi Al-Naqeeb
Middle Euphrates Cancer Research Unit, College of Medicine, University of Kufa, Iraq
Liqaa Hadi Naser
Middle Euphrates Cancer Research Unit, College of Medicine, University of Kufa, Iraq
Zainab Abd Al_hassan Zwain
Middle Euphrates Cancer Research Unit, College of Medicine, University of Kufa, Iraq
Ayat Raad jawad
Middle Euphrates Cancer Research Unit, College of Medicine, University of Kufa, Iraq
Saif Jabbar Yasir
Middle Euphrates Cancer Research Unit, College of Medicine, University of Kufa, Iraq

03Article Details

Section
Articles Publishing terms and rules
Pages
46-68
Published
2026-10-31

How to Cite

Advances and Prospects in Next-Generation CRISPR-Based Cancer Diagnostics: CRISPR. (2026). International Journal of Environmental and Biological Sciences, 1(4), 46-68. https://doi.org/10.63939/shjcp156

04References

  1. 1. Yazdi, Z.F. et al. (2024) “Recent progress in prompt molecular detection of liquid biopsy using Cas enzymes: innovative approaches for cancer diagnosis and analysis,” Journal of Translational Medicine, 22(1), p. 1173. doi:10.1186/s12967-024-05908-y.
  2. 2. Wang, K. et al. (2023) “Liquid biopsy techniques and pancreatic cancer: diagnosis, monitoring, and evaluation,” Molecular Cancer, 22(1). doi:10.1186/s12943-023-01870-3.
  3. 3. Rahimi, S. et al. (2024) “CRISPR-Cas target recognition for sensing viral and cancer biomarkers,” Nucleic Acids Research, 52(17), pp. 10040–10067. doi:10.1093/nar/gkae736.
  4. 4. Dongen, J.E. van and Segerink, L.I. (2025) “Building the Future of Clinical Diagnostics: An Analysis of Potential Benefits and Current Barriers in CRISPR/Cas Diagnostics,” ACS Synthetic Biology, 14(2), pp. 323–331. doi:10.1021/acssynbio.4c00816.
  5. 5. Wang, M. et al. (2023) “CRISPR applications in cancer diagnosis and treatment,” Cellular & Molecular Biology Letters, 28(1), p. 73. doi:10.1186/s11658-023-00483-4.
  6. 6. Singh, S. et al. (2022) “Tailored point-of-care biosensors for liquid biopsy in the field of oncology,” Lab on a Chip, 23(1), pp. 44–61. doi:10.1039/d2lc00666a.
  7. 7. Zhou, Z., Cho, I. and Kadam, U.S. (2025) “CRISPR-Cas-Based Diagnostics in Biomedicine: Principles, Applications, and Future Trajectories,” Biosensors, 15(10), p. 660. doi:10.3390/bios15100660.
  8. 8. Feng, W. et al. (2021) “CRISPR technology incorporating amplification strategies: molecular assays for nucleic acids, proteins, and small molecules,” Chemical Science, 12(13), pp. 4683–4698. doi:10.1039/d0sc06973f.
  9. 9. Rossetti, M. et al. (2022) “Enhancement of CRISPR/Cas12a trans-cleavage activity using hairpin DNA reporters,” Nucleic Acids Research, 50(14), pp. 8377–8391. doi:10.1093/nar/gkac578.
  10. 10. Kaminski, M.M. et al. (2021) “CRISPR-based diagnostics,” Nature Biomedical Engineering, 5(7), pp. 643–656. doi:10.1038/s41551-021-00760-7.
  11. 11. Huyke, D.A. et al. (2022) “Enzyme Kinetics and Detector Sensitivity Determine Limits of Detection of Amplification-Free CRISPR-Cas12 and CRISPR-Cas13 Diagnostics,” Analytical Chemistry, 94(27), pp. 9826–9834. doi:10.1021/acs.analchem.2c01670.
  12. 12. Qian, X. et al. (2024) “CRISPR for companion diagnostics in low-resource settings,” Lab on a Chip, 24(20), pp. 4717–4740. doi:10.1039/d4lc00340c.
  13. 13. Slattery, J.R. et al. (2025) “CRISPR-Powered Liquid Biopsies in Cancer Diagnostics,” Cells, 14(19), p. 1539. doi:10.3390/cells14191539.
  14. 14. Zhou, Y. et al. (2024) “Tumor biomarkers for diagnosis, prognosis and targeted therapy,” Signal Transduction and Targeted Therapy, 9(1), p. 132. doi:10.1038/s41392-024-01823-2.
  15. 15. Darbeheshti, F. and Makrigiorgos, G.M. (2023) “Enzymatic Methods for Mutation Detection in Cancer Samples and Liquid Biopsies,” International Journal of Molecular Sciences, 24(2), p. 923. doi:10.3390/ijms24020923.
  16. 16. Liu, Z. et al. (2024) “Microfluidic biosensors for biomarker detection in body fluids: a key approach for early cancer diagnosis,” Biomarker Research, 12(1), p. 153. doi:10.1186/s40364-024-00697-4.
  17. 17. Sarhadi, V.K. and Armengol, G. (2022) “Molecular Biomarkers in Cancer,” Biomolecules, 12(8), p. 1021. doi:10.3390/biom12081021.
  18. 18. Palaz, F. et al. (2021) “CRISPR-Cas13 System as a Promising and Versatile Tool for Cancer Diagnosis, Therapy, and Research,” ACS Synthetic Biology, 10(6), pp. 1245–1267. doi:10.1021/acssynbio.1c00107.
  19. 19. Hong, J. et al. (2023) “CRISPR/Cas13a‐Based MicroRNA Detection in Tumor‐Derived Extracellular Vesicles,” Advanced Science, 10(24). doi:10.1002/advs.202301766.
  20. 20. Liu, Yin et al. (2021) “EasyCatch, a convenient, sensitive and specific CRISPR detection system for cancer gene mutations,” Molecular Cancer, 20(1), p. 157. doi:10.1186/s12943-021-01456-x.
  21. 21. Tenchov, R. et al. (2024) “Biomarkers for Early Cancer Detection: A Landscape View of Recent Advancements, Spotlighting Pancreatic and Liver Cancers,” ACS Pharmacology & Translational Science, 7(3), pp. 586–613. doi:10.1021/acsptsci.3c00346.
  22. 22. Yu, D. et al. (2022) “Exosomes as a new frontier of cancer liquid biopsy,” Molecular Cancer, 21(1), p. 56. doi:10.1186/s12943-022-01509-9.
  23. 23. Ma, L. et al. (2024) “Liquid biopsy in cancer: current status, challenges and future prospects,” Signal Transduction and Targeted Therapy, 9(1), p. 336. doi:10.1038/s41392-024-02021-w.
  24. 24. Nikanjam, M., Kato, S. and Kurzrock, R. (2022) “Liquid biopsy: current technology and clinical applications,” Journal of Hematology & Oncology, 15(1), p. 131. doi:10.1186/s13045-022-01351-y.
  25. 25. Ghosh, S. et al. (2024) “Harnessing exosomes as cancer biomarkers in clinical oncology,” Cancer Cell International, 24(1), p. 278. doi:10.1186/s12935-024-03464-5.
  26. 26. Salmond, N. and Williams, K.C. (2021) “Isolation and characterization of extracellular vesicles for clinical applications in cancer – time for standardization,” Nanoscale Advances, 3(7), pp. 1830–1852. doi:10.1039/d0na00676a.
  27. 27. Moding, E.J. et al. (2021) “Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease,” Cancer Discovery, 11(12), pp. 2968–2986. doi:10.1158/2159-8290.cd-21-0634.
  28. 28. Passaro, A. et al. (2024) “Cancer biomarkers: Emerging trends and clinical implications for personalized treatment,” Cell, 187(7), pp. 1617–1635. doi: 10.1016/j.cell.2024.02.041.
  29. 29. Deveson, I.W. et al. (2021) “Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology,” Nature Biotechnology, 39(9), pp. 1115–1128. doi:10.1038/s41587-021-00857-z.
  30. 30. Dasari, A. et al. (2020) “ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper,” Nature Reviews Clinical Oncology, 17(12), pp. 757–770. doi:10.1038/s41571-020-0392-0.
  31. 31. Tivey, A. et al. (2022) “Circulating tumour DNA — looking beyond the blood,” Nature Reviews Clinical Oncology, 19(9), pp. 600–612. doi:10.1038/s41571-022-00660-y.
  32. 32. Ntzifa, A. and Lianidou, E. (2023) “Pre-analytical conditions and implementation of quality control steps in liquid biopsy analysis,” Critical Reviews in Clinical Laboratory Sciences, 60(8), pp. 573–594. doi:10.1080/10408363.2023.2230290.
  33. 33. Williams, P.M. et al. (2021) “Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of Health,” JCO Precision Oncology, 5(5), pp. 910–920. doi:10.1200/po.20.00528.

Most read articles by the same author(s)